000			03788nam a22004095i 4500
999			_c9640 _d9640
001			9640
003			DE-He213
005			20210518040406.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			171109s2018 gw | s |||| 0|eng d
020			_a9783319602769
024	7		_a10.1007/978-3-319-60276-9 _2doi
040			_aES-MaUEC _bspa _dES-VaUE
050		4	_aRC862 _b.T743 2018 EB
245	1	0	_aTreatment of Inflammatory Bowel Disease with Biologics _cedited by Adam S. Cheifetz, Joseph D. Feuerstein.
264		1	_aCham _bSpringer International Publishing : _bImprint: Springer _c2018.
300			_a1 recurso en línea (XI, 335 páginas 22 ilustraciones, 19 ilustraciones a color)
336			_2rdacontent _aTexto (visual) _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aMedicine (Springer-11650)
505	0		_aMechanism of Action and Pharmacokinetics of Biologics -- Anti-tumor Necrosis Factor Agents in Ulcerative Colitis -- Anti-tumor Necrosis Factor Agents in Crohn’s Disease -- Anti-TNF Therapy for Treatment of Extraintestinal Manifestations of Inflammatory Bowel Disease -- Use of Biologics in the Postoperative Management of Crohn’s Disease -- Biologics in Pregnancy and Breastfeeding -- Concomitant Use of Immunosuppressive Therapy with Tumor Necrosis Factor (TNF) Antagonists in Inflammatory Bowel Disease -- Therapeutic Drug Monitoring of Biologic Agents -- Use of Biologics in Crohn’s Disease and Ulcerative Colitis Prior to Surgery and Perioperative Risks -- Cessation of Biologics – Can it be Done? -- Biologic Therapy in Pediatric Inflammatory Bowel Disease -- Infectious Complications of Biologics -- Tumor Necrosis Factor-Alpha Inhibitors and Risks of Malignancy -- Non-infectious and Non-malignant Complications of Biologics -- Biosimilars in Inflammatory Bowel Disease 2017: State of the Science, State of the Art, State of the Finances -- Anti-Integrin Agents in IBD: Efficacy and Risk of Complications -- Novel Agents in Inflammatory Bowel Disease -- Quality, Safety, and Practical Considerations of Using Biologic Therapies. .
520	3		_aThis book is a concise yet comprehensive overview of the use of biologics for the treatment of Crohn’s disease and ulcerative colitis. The volume details how best to utilize these medications in order to optimize their efficacy and safety, as well as how to understand, recognize, and treat complications that may arise from using biologics to treat IBD. The text also focuses on new data, novel biologics, and biosimilars of this rapidly expanding field. Written by experts in the field, Treatment of Inflammatory Bowel Disease with Biologics is a valuable resource for gastroenterologists, allied health professionals, fellows, and trainees who treat patients with inflammatory bowel disease.
650		7	_aEnfermedad inflamatoria intestinal _9160162 _2embne
650		7	_9141308 _aGastroenterología _2embne
700	1		_aCheifetz, Adam S _eeditor literario _0http://id.loc.gov/authorities/names/n2010182768 _0http://viaf.org/viaf/129252794
700	1		_aFeuerstein, Joseph D _eeditor literario _0http://id.loc.gov/authorities/names/n2018183811 _0http://viaf.org/viaf/15152682575523312799
710	2		_aSpringerLink (Online service) _0http://id.loc.gov/authorities/names/no2005046756 _0http://viaf.org/viaf/148105729 _9106996
776	0	8	_iEdición impresa: _z9783319602752
776	0	8	_iEdición impresa: _z9783319602776
776	0	8	_iEdición impresa: _z9783319868233
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-60276-9 _zAcceso a este recurso digital (usuarios Universidad Europea de Valencia)
942			_2lcc _cLE
998			_db